OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012

Seminar will Discuss OGT’s Integrated Biomarker Discovery Solutions

Oxford, UK – 10 February 2012.Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be exhibiting and presenting its biomarker discovery service at the Molecular Medicine Tri-Con in San Francisco, California (19th-23rd February 2012). The conference, organized by the Cambridge Healthtech Institute, will include an OGT presentation entitled “Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success”, taking place on Tuesday 21st February at 15.50 in the Moscone North Convention Centre. The talk, given by Dr Graham Speight, Head of Genomic Biomarkers at OGT, will explain how high-throughput biomarker discovery can generate rich datasets identifying a number of biologically relevant disease markers, making it useful for validation, proof of concept and in depth analysis.

Will Colón, OGT’s Business Development Director, Biomarker Discovery, commented: “OGT’s expertise in genomic- and protein- based arrays makes us ideally placed to offer a powerful, integrated range of biomarker discovery solutions. As well as DNA arrays, we have developed a unique “functional protein” array technology, which conserves the in vivo conformation of each protein when attached to the surface of the array. This enables the discovery of autoantibody biomarkers with maximum sensitivity and specificity. Utilising our high-throughput workflow procedures, and over 140 quality control steps, our biomarker discovery service uses only the minimum amount of precious clinical sample necessary to produce insightful results.”

As well as exhibiting and presenting at the conference, OGT will also provide details of its Genefficiency™ genomic products and services as part of the Molecular Medicine Tri-Con product showcase. This will include OGT’s Targeted Sequencing Service, which is designed to provide meaningful results rather than insurmountable data sets, achieved via OGT’s internationally recognised probe design, data analysis expertise and independently- accredited quality control procedures. This service has recently been extended to cover the genomic analysis of rare diseases, providing an option specifically optimised to help investigators and clinicians identify causative mutations quickly, easily and without the need for in-house practical or bioinformatics expertise.

OGT has recently infused some of its expertise on biomarkers into a white paper entitled “Autoantibody biomarker panels for improved disease diagnosis”. This can be downloaded from the OGT website and will also be freely available as a hard copy at OGT’s booth (# 506), where OGT experts will also be on hand to discuss how they can help with your biomarker discovery programme, adding value from concept to completion.

To find out more about the full range of products and services offered by OGT, visit www.ogt.co.uk.

For further information, please contact:

Oxford Gene Technology,
Begbroke Science Park,
Sandy Lane,
Oxford OX5 1PF
T: +44 (0) 1865 856826
F: +44 (0) 1865 848684
E: [email protected]
W: www.ogt.co.uk